Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

11.42
-0.4200-3.55%
Post-market: 11.420.00000.00%16:10 EDT
Volume:332.73K
Turnover:3.81M
Market Cap:155.31M
PE:-2.86
High:11.95
Open:11.93
Low:11.24
Close:11.84
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:11.92M
Volume Ratio:0.72
T/O Rate:2.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:1.22
PE(LYR):-1.83

Loading ...

Immunic Director Duane Nash Resigns, Board Shrinks to Nine Members

Reuters
·
Just now

Leerink Partners Sticks to Its Buy Rating for Immunic (IMUX)

TIPRANKS
·
Sep 10

Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Celldex (CLDX)

TIPRANKS
·
Sep 10

Immunic Price Target Maintained with a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

Immunic Highlights Multiple Sclerosis Program in R&D Webinar

TIPRANKS
·
Sep 09

Immunic Posts Investor Overview Presentation on Multiple Sclerosis Strategy

Reuters
·
Sep 04

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day

Reuters
·
Sep 02

Analyst Reiterates Buy on Immunic, Sees Undervalued MS Opportunity with Unchanged $56 Price Target

TIPRANKS
·
Sep 02

Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating

MT Newswires Live
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 01

Immunic price target raised to $29 from $19 at Roth Capital

TIPRANKS
·
Sep 01

Immunic Appoints Chitrang Davé as Chief Data and Digital Officer

Reuters
·
Sep 01

Immunic Appoints Chitrang DavÉ as Chief Data and Digital Officer

THOMSON REUTERS
·
Sep 01

Immunic initiated with an Outperform at Wedbush

TIPRANKS
·
Aug 17

Wedbush Initiates Immunic at Outperform With $45 Price Target

MT Newswires Live
·
Aug 17

Sam Slutsky Initiates Buy on Immunic, Citing Late-Stage MS Program, Expansion into Progressive MS, and Strengthened Nurr1-Focused Pipeline

TIPRANKS
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Aug 12

Immunic Posts Investor Presentation Highlighting Vidofludimus Calcium Phase 3 MS Program

Reuters
·
Aug 11

Immunic Q2 Loss Per Share USD 0.80

THOMSON REUTERS
·
Aug 11

Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate

Benzinga Earnings
·
Aug 11